WBSCR17 Inhibitors
WBSCR17 inhibitors belong to a category of chemical agents designed to interfere selectively with the function of the protein encoded by the WBSCR17 gene, also known as Williams-Beuren syndrome chromosome region 17. The protein plays a crucial role in various biological pathways, and its inhibition can lead to changes in cellular processes. The inhibitors are typically small molecules that can bind to the active or allosteric sites of the WBSCR17 protein, thus preventing it from performing its normal biological functions. The design of these inhibitors often involves a comprehensive understanding of the protein's structure and the key interactions that are essential for its activity. By disrupting these interactions, WBSCR17 inhibitors can modulate the activity of the protein in a precise manner.
The development of WBSCR17 inhibitors requires detailed research into the molecular dynamics of the WBSCR17 protein, including its 3D conformation and the way it interacts with other cellular components. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling are employed to gain insights into the binding sites and the conformational changes that the protein undergoes upon ligand binding. With this information, chemists can synthesize inhibitors that fit into the protein's structure like a key in a lock, ensuring specificity and reducing the likelihood of off-target effects. The specificity of WBSCR17 inhibitors is crucial, as it determines their ability to modulate the protein's function without interfering with other proteins that may have similar structures or functions. The chemical properties of these inhibitors, such as solubility, stability, and reactivity, are also fine-tuned to ensure that they can reach their target effectively and maintain their inhibitory action within the complex environment of a living organism.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin acts by inhibiting mTOR (mechanistic target of rapamycin) kinase, which is a part of mTOR signaling pathway. Since WBSCR17 is implicated in the regulation of autophagy and lysosomal function, inhibition of mTOR by rapamycin could lead to altered protein degradation pathways, thereby indirectly inhibiting WBSCR17 function. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is a lysosomotropic agent that prevents endosomal acidification, which can impact lysosomal enzyme function and autophagy. WBSCR17, being associated with lysosomal biogenesis, may have its function indirectly inhibited due to disruption of the autophagic and lysosomal degradation pathways. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of vacuolar-type H+-ATPase (V-ATPase). By inhibiting V-ATPase, it disrupts lysosomal acidification and autophagy, which could reduce WBSCR17 function since WBSCR17 is involved in lysosomal biogenesis and function. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine inhibits autophagy by blocking autophagosome formation through the inhibition of class III phosphatidylinositol 3-kinases (PI3K). Given WBSCR17's role in lysosomal function, inhibiting autophagosome formation may indirectly inhibit WBSCR17 activity. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 is known to promote the degradation of class III PI3K Vps34 complexes, thereby inhibiting autophagy. This action can indirectly inhibit WBSCR17 by altering the autophagic flux and lysosomal function, which are associated with WBSCR17. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide acts by inhibiting eukaryotic protein synthesis. As WBSCR17 is a protein, the inhibition of protein synthesis can indirectly inhibit the availability and function of WBSCR17 by preventing its production. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins. As WBSCR17 is involved in protein quality control, the dysregulation of proteasomal degradation can indirectly affect the function of WBSCR17. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A, like Bafilomycin A1, is a V-ATPase inhibitor that impairs lysosomal acidification. This could lead to an indirect reduction in WBSCR17 function by affecting lysosomal enzyme activities and the autophagic process. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E64d is a selective inhibitor of cysteine proteases. By inhibiting these enzymes, it affects protein degradation pathways within the lysosome. This can lead to an indirect inhibition of WBSCR17, which is involved in the regulation of lysosomal function. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor that can block apoptosis. Since apoptosis involves lysosomal degradation and release of lysosomal enzymes, inhibiting caspases may have an indirect effect on WBSCR17 function by stabilizing the intracellular environment. | ||||||